Apimeds Pharmaceuticals US Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Apitox (LT-100) Clinical Trial Progress QuarterlyTarget: Initiation of confirmatory Phase 3 clinical trial in knee osteoarthritis (OA)
Digital Asset Portfolio Fair Value Quarterly127.8MTarget: Stabilization and yield generation via AI-driven treasury platform
Biopharmaceutical Operating Revenue Annually0.0Target: 0 (Pre-revenue clinical-stage biopharmaceutical operations)
Watch Items
- NYSE American Continued Listing ComplianceTrigger: Overdue Form 10-K filing for fiscal year ended December 31, 2025 (Notice of non-compliance received April 17, 2026)Action: Submit a remediation plan to NYSE American and file the overdue Form 10-K within the initial cure period ending October 15, 2026
- FDA Alignment on LT-100 (Apitox) Development PathTrigger: Type C meeting with FDA Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) scheduled for May 4, 2026Action: Incorporate FDA feedback on manufacturing process enhancements and route of administration updates into the Phase 3 trial protocol
- Going Concern and Liquidity ManagementTrigger: Accumulated deficit of $45.45 million and net loss of $35.06 million as of March 31, 2026Action: Execute additional tranches under the $120.9 million PIPE facility and continue sales of NILA tokens for USDT to ensure operational liquidity
Research as of 20 Jun 2026